251 related articles for article (PubMed ID: 31870793)
1. Tumour associated glycans: A route to boost immunotherapy?
Scott E; Elliott DJ; Munkley J
Clin Chim Acta; 2020 Mar; 502():167-173. PubMed ID: 31870793
[TBL] [Abstract][Full Text] [Related]
2. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
RodrÍguez E; Schetters STT; van Kooyk Y
Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
[TBL] [Abstract][Full Text] [Related]
3. Using the glycan toolbox for pathogenic interventions and glycan immunotherapy.
Li RE; van Vliet SJ; van Kooyk Y
Curr Opin Biotechnol; 2018 Jun; 51():24-31. PubMed ID: 29175707
[TBL] [Abstract][Full Text] [Related]
4. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
Front Immunol; 2020; 11():564499. PubMed ID: 33133075
[TBL] [Abstract][Full Text] [Related]
5. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
6. Glycans as shapers of tumour microenvironment: A sweet driver of T-cell-mediated anti-tumour immune response.
Fernandes Â; Azevedo CM; Silva MC; Faria G; Dantas CS; Vicente MM; Pinho SS
Immunology; 2023 Feb; 168(2):217-232. PubMed ID: 35574724
[TBL] [Abstract][Full Text] [Related]
7. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Galon J; Bruni D
Nat Rev Drug Discov; 2019 Mar; 18(3):197-218. PubMed ID: 30610226
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis.
Rodrigues JG; Balmaña M; Macedo JA; Poças J; Fernandes Â; de-Freitas-Junior JCM; Pinho SS; Gomes J; Magalhães A; Gomes C; Mereiter S; Reis CA
Cell Immunol; 2018 Nov; 333():46-57. PubMed ID: 29576316
[TBL] [Abstract][Full Text] [Related]
9. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development.
Ochoa de Olza M; Navarro Rodrigo B; Zimmermann S; Coukos G
Lancet Oncol; 2020 Sep; 21(9):e419-e430. PubMed ID: 32888471
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the anti-tumour immune response by cancer-associated fibroblasts.
Harper J; Sainson RC
Semin Cancer Biol; 2014 Apr; 25():69-77. PubMed ID: 24406209
[TBL] [Abstract][Full Text] [Related]
11. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Flower KJ; Ghaem-Maghami S; Brown R
Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.
Thurin M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):89-100. PubMed ID: 34161162
[TBL] [Abstract][Full Text] [Related]
13. Recognition of tumor glycans by antigen-presenting cells.
Aarnoudse CA; Garcia Vallejo JJ; Saeland E; van Kooyk Y
Curr Opin Immunol; 2006 Feb; 18(1):105-11. PubMed ID: 16303292
[TBL] [Abstract][Full Text] [Related]
14. Cell surface glycan-lectin interactions in tumor metastasis.
Rambaruth ND; Dwek MV
Acta Histochem; 2011 Oct; 113(6):591-600. PubMed ID: 21501858
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
16. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
Nagarsheth N; Wicha MS; Zou W
Nat Rev Immunol; 2017 Sep; 17(9):559-572. PubMed ID: 28555670
[TBL] [Abstract][Full Text] [Related]
17. Glycans as targets for therapeutic antitumor antibodies.
Rabu C; McIntosh R; Jurasova Z; Durrant L
Future Oncol; 2012 Aug; 8(8):943-60. PubMed ID: 22894669
[TBL] [Abstract][Full Text] [Related]
18. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
19. Toward integrative cancer immunotherapy: targeting the tumor microenvironment.
Emens LA; Silverstein SC; Khleif S; Marincola FM; Galon J
J Transl Med; 2012 Apr; 10():70. PubMed ID: 22490302
[TBL] [Abstract][Full Text] [Related]
20. Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.
Ren X; Lin S; Guan F; Kang H
Int J Biol Sci; 2024; 20(7):2607-2621. PubMed ID: 38725856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
